U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
Brief: GRI Bio Reports 6-Week Interim Lung Function Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis
U.S. STOCKS ON THE MOVE -Apple, Enovix, Kroger
GRI Bio climbs on lung disease drug trial data
GRI Bio Inc expected to post a loss of $1.31 a share - Earnings Preview
Brief: GRI Bio Reports 6-Week Interim Biomarker Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis (“Ipf”)
Brief: GRI Bio Completes Enrollment In Phase 2A Study Of GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis (“IPF”)
Brief: GRI Bio Inc - Phase 2A Study Results For GRI-0621 Expected In Q2 2025
GRI Bio Inc reports results for the quarter ended March 31 - Earnings Summary
GRI Bio Inc expected to post a loss of $4.08 a share - Earnings Preview
Brief: GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621
Brief: GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis
U.S. RESEARCH ROUNDUP-Lowe's Companies, Netflix, Vulcan Materials
Brief: Gri Bio Announces Closing Of $5.0 Million Public Offering
Brief: Gri Bio Inc - IDMC Recommends Continuation Of Study With No Safety Concerns
GRI Bio Inc reports results for the quarter ended September 30 - Earnings Summary
GRI Bio Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Gri Bio Granted Japan Patent For NKT Cell Modulators
Brief: Gri Bio Receives Authorization To Conduct Phase 2A Biomarker Study Evaluating Gri-0621 In Australia